Considering the Experimental Use of Temozolomide in Glioblastoma Research

Temozolomide (TMZ) currently remains the only chemotherapeutic component in the approved treatment scheme for Glioblastoma (GB), the most common primary brain tumour with a dismal patient’s survival prognosis of only ~15 months. While frequently described as an alkylating agent that causes DNA damag...

Descripción completa

Detalles Bibliográficos
Autores principales: Herbener, Verena J., Burster, Timo, Goreth, Alicia, Pruss, Maximilian, von Bandemer, Hélène, Baisch, Tim, Fitzel, Rahel, Siegelin, Markus D., Karpel-Massler, Georg, Debatin, Klaus-Michael, Westhoff, Mike-Andrew, Strobel, Hannah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344626/
https://www.ncbi.nlm.nih.gov/pubmed/32512726
http://dx.doi.org/10.3390/biomedicines8060151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344626/
https://www.ncbi.nlm.nih.gov/pubmed/32512726
http://dx.doi.org/10.3390/biomedicines8060151

Ejemplares similares